Floatz logo

Palbociclib

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Helwan UniversitySmall moleculePhase 2Active
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
95/ 100

Competitive context

191 Active assets in the Human Epidermal Growth Factor 2 Negative Carcinoma of Breast cohort.

Asset / SponsorPhaseRating
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Inno-206
Roswell Park Cancer Institute
Phase 3BB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Capecitabine
Kristina A. Fanucci
Phase 4BB

View all 50 →

Same molecule, other indications

Palbociclib is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →